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Background: Ginsenoside-Rg3, the pharmacologically active component of red ginseng, has been found
to inhibit tumor growth, invasion, metastasis, and angiogenesis in various cancer models. Previously, we
found that 20(R)-ginsenoside-Rg3 (Rg3) could inhibit angiogenesis. Since microRNAs (miRNAs) have
been shown to affect many biological processes, they might play an important role in ginsenoside-
mediated angiomodulation.
Methods: In this study, we examined the underlying mechanisms of Rg3-induced angiosuppression
through modulating the miRNA expression. In the miRNA-expression proﬁling analysis, six miRNAs and
three miRNAs were found to be up- or down-regulated in vascular-endothelial-growth-factor-induced
human-umbilical-vein endothelial cells (HUVECs) after Rg3 treatment, respectively.
Results: A computational prediction suggested that mature hsa-miR-520h (miR-520h) targets ephrin
receptor (Eph) B2 and EphB4, and hence, affecting angiogenesis. The up-regulation of miR-520h after Rg3
treatment was validated by quantitative real-time polymerase chain reaction, while the protein ex-
pressions of EphB2 and EphB4 were found to decrease, respectively. The mimics and inhibitors of miR-
520h were transfected into HUVECs and injected into zebra-ﬁsh embryos. The results showed that
overexpression of miR-520h could signiﬁcantly suppress the EphB2 and EphB4 protein expression,
proliferation, and tubulogenesis of HUVECs, and the subintestinal-vessel formation of the zebra ﬁsh.
Conclusion: These results might provide further information on the mechanism of Rg3-induced angio-
suppression and the involvement of miRNAs in angiogenesis.
Copyright 2015, The Korean Society of Ginseng, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Panax ginseng Meyer has been applied as general “tonic” and
therapeutics for many years in Asian countries. Its diverse phar-
macological activities are largely attributed to ginsenosides, the
major active component found in ginseng. Among the ginseno-
sides, 20(R)-ginsenoside-Rg3 (Rg3) (Fig. 1), a partially deglycosy-
lated saponin that presents in relatively large quantity in red
ginseng, has been shown as a potent angiosuppressive and anti-
tumor agent [1e3]. Our previous ﬁndings demonstrated that Rg3
could suppress human-umbilical-vein-endothelial-cell (HUVEC)
proliferation, tubulogenesis, and vascular-endothelial-growth-wer, Hong Kong Baptist University,
ower, Hong Kong Baptist Universi
ong), Patrick@hkbu.edu.hk (P.Y.-K
ht 2015, The Korean Society of Gi
d/4.0/).factor (VEGF)-induced chemoinvasion; in vivo neovessel forma-
tion in a Matrigel plug model; and endothelial sprouting and
matrix-metalloproteinase production in cultured aortic explants
[3]. Moreover, it has been shown that the combined application of
Rg3 with different conventional chemotherapeutic drugs,
including capecitabine, cyclophosphamide, or gemcitabine, could
signiﬁcantly inhibit the intratumoral microvessel formation of
tumor tissues in mice implanted with breast or lung carcinoma
[4e8].
However, it has beenwell accepted that VEGF plays a critical role
in tumor progression, metastasis, as well as angiogenesis. A large
amount of VEGF is being produced by the hypoxic tumor tissues toHong Kong
ty, Hong Kong
. Yue).
nseng, Published by Elsevier. This is an open access article under the CC BY-NC-ND
Fig. 1. The chemical structure of 20(R)-ginsenoside Rg3.
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showed that Rg3 could signiﬁcantly inhibit VEGF and VEGF receptor
expression in HUVECs, tumor tissues, and animal sera of tumor-
bearing mice [9]. To this end, we employed this VEGF-mediated
angiogenesis model in our angiosuppressive studies, in which
HUVECs were induced with VEGF to mimic the tumor microenvi-
ronment. Obviously, Rg3 was found to exhibit a more signiﬁcant
angiosuppressive effect in the VEGF-activated HUVECs. In the
present study, in order to investigate the microRNA (miRNAs)-
mediated angiosuppressive mechanism of Rg3, the miRNA-
expression proﬁle was determined in the VEGF-activated HUVECs
upon Rg3 treatment.
A growing body of evidence indicates that miRNAs, a group of
small noncoding RNAs that regulate gene expression post-
transcriptionally, play an important role in regulating diverse
cellular processes, such as proliferation, differentiation, cell cycle,
and apoptosis [10,11]. They have also been suggested as molecular
determinants of many physiological and pathological processes
[12,13]. Previously, we have extended our ginseng pharmacological
studies to the miRNA-mediated biochemical pathways. We showed
that ginsenoside Rg1-induced angiogenesis could be mediated by a
group of miRNAs as determined by a microarray-based miRNA
experiment, in which down-regulated miR-214 and miR-15b were
found to correlate with the increased production of angiogenic
factor, endothelial nitric oxide synthase [14], and angiogenic re-
ceptor, VEGF receptor 2 (VEGFR-2) [15], in HUVECs. These data
strongly indicated that miRNAs play an important role in
ginsenoside-mediated angiomodulation. Therefore, we speculated
that Rg3 may also modulate the miRNA expression that leads to
inhibit angiogenesis.
In the present study, a miRNA-expression proﬁling analysis was
performed to select the miRNA candidates involved in the Rg3-
induced angiosuppression. Again, gain-of-function and loss-of-
function experiments were used to investigate the functional
roles of the target miRNAs.
2. Materials and methods
2.1. Chemicals
Rg3 (Fig. 1) is a reference compound (purity > 98%) purchased
from the Division of Chinese Materia Medica and Natural Products,
National Institute for the Control of Pharmaceutical and Biological
Products, Ministry of Public Health, China. A stock solution of
20(R)-Rg3 at 50mM was prepared in dimethyl sulfoxide.
2.2. Cell culture
HUVECs (Lonza, Allendale, NJ, USA)were grown inM199medium
supplemented with 20 mg/mL endothelial-cell-growth supplement,90 mg/mL heparin (Sigma, Saint Louis, MO, US), 20% heat-inactivated
fetal bovine serum (HI-FBS), and 1% penicillinestreptomycin (Invi-
trogen, Boston, MA, USA) on 0.1% gelatin-coated culture ﬂasks. The
cells were grown at 37C in a humidiﬁed incubator with 5% CO2.
HUVECs from passages 2e6 were used in this study.
2.3. The miRNA-microarray analysis [14]
2.3.1. Small RNA isolation
VEGF-induced HUVECs were treated with 100nM Rg3 in M199
supplemented with 10% HI-FBS for 24 h. The control experiment
was set up in parallel by culturing HUVECs without Rg3. Total RNA
was extracted using the TRIzol Reagent (Invitrogen); the quantity
and integrity of the RNA preparation were assessed by measuring
optical density at 260 nm using the NanoDrop ND-1000 Spectro-
photometer (NanoDrop Technologies, Wilmington, DE, USA) and
agarose gel electrophoresis, respectively. The small RNA was puri-
ﬁed and enriched through a column-based method using the
PureLink miRNA Isolation Kit (Invitrogen).
2.3.2. The miRNA labeling and microarray hybridization
Small cellular RNAs extracted from the VEGF-induced HUVECs
(control) and the Rg3-treated VEGF-induced HUVECs (treatment)
were polyadenylated at the 30-end by NCode miRNA Labeling Sys-
tem (Invitrogen), and ligated with capture sequences in Alexa Fluor
5 Ligation Mix or Alexa Fluor 3 Ligation Mix separately. The tagged
miRNA was puriﬁed by spin-column-based centrifugation, and
immediately hybridized with miRNA microarray (NCode Multi-
Species miRNA Microarray Kit V2, Invitrogen) at 52C for 16 h. Af-
ter hybridization, the microarray slides were washed and spin
dried, and subsequently labeled with Alexa Fluor 3 and Alexa Fluor
5 correspondingly in the dark at 62C for 4 h. The slides were
washed and spin dried before scanning.
2.3.3. Microarray imaging and data analysis
The miRNA microarrays were screened using the ScanArray
5000 confocal laser scanner (Packard BioChip Technologies/GSI
Lumonics) at 556 nm and 650 nm for Alexa Fluor 3 and Alexa Fluor
5, respectively. The ﬂuorescent signals of Alexa Fluor 3 and 5 on
each spot were quantiﬁed by QuantArray quantitative microarray
analysis software (GSI Lumonics). Using GeneSpring GX software
(version 10.0; Agilent Technologies, Palo Alto, CA, USA), the spot
signals were further analyzed and normalized by locally weighted
regression scatterplot smoothing, where 20% of the data were used
for smoothing and the cutoff value was 10.0. The miRNA expression
was considered down- or up-regulated if the fold change in
expression level (Rg3 þ VEGF/VEGF) was  2 or  2, respectively.
2.4. Transient transfection with miRNA inhibitor or precursor
mimics
HUVECs were transfected with Pre-miR miRNA Precursor (Pre-
miR-520h) or Anti-miR miRNA Inhibitor (AS-miR-520h) (20nM)
(Ambion, Grand Island, NY, USA) using Lipofectamine 2000 in Opti-
MEM I Reduced Serum Medium (Invitrogen). Pre-miR miRNA Pre-
cursor Negative Control #1 (precontrol) and Anti-miR miRNA In-
hibitor Negative Control #1 (AS-control) (Ambion) were used as
negative controls in the experiments involving Pre-miR miRNA
Precursor and Anti-miR miRNA Inhibitor, respectively. The total
RNA and cell lysate were collected for the indicated assays.
2.5. Quantitative real-time polymerase chain reaction
The total RNA (10 ng) extracted from the cells was converted to
complementary DNA (cDNA) using TaqMan MicroRNA Reverse
Table 1
Differentially expressed microRNAs after 20(R)-ginsenoside-Rg3 treatment in
vascular-endothelial-growth-factor-induced human umbilical vein endothelial cells
Mature
miRNAs
Mature miRNA
sequence (50e30)
miRBase
accession
number
Fold change
(VEGF þ Rg3/
VEGF)
Up-regulated miRNAs
hsa-miR-520h acaaagugcuucccuuuagagu MIMAT0002867 15.32  3.9
hsa-miR-487b aaucguacagggucauccacuu MIMAT0003180 10.10  4.29
hsa-miR-197 uucaccaccuucuccacccagc MIMAT0000227 6.89  2.28
hsa-miR-524* cuacaaagggaagcacuuucuc MIMAT0002849 3.02  1.01
hsa-miR-342 ucucacacagaaaucgcacccgu MIMAT0000753 2.58  0.85
hsa-miR-219 ugauuguccaaacgcaauucu MIMAT0000276 2.26  0.7
Downregulated miRNAs
hsa-miR-23a aucacauugccagggauuucc MIMAT0000078 3.81  1.94
hsa-miR-489 gugacaucacauauacggcagc MIMAT0002805 4.95  2.56
hsa-miR-377 aucacacaaaggcaacuuuugu MIMAT0000730 34.94  15.03
VEGF-induced HUVECs were treated with or without Rg3 (100nM) for 24 h.
Extracted small RNAs were ﬂuorescently labeled with Alexa Fluor 5 or 3, and hy-
bridized onto miRNA microarray. The miRNA expression was considered up- or
downregulated if the fold change in the expression level detected in Rg3-treated
group (Rg3 þ VEGF) versus control group (VEGF alone) was over 2 or below 2,
respectively. Three individual experiments were performed, and each miRNA was
spotted on the microarray chip in triplicate. Values of fold change are presented as
mean  standard error of the mean
HUVEC, human umbilical vein endothelial cell; miRNA, microRNA; VEGF, vascular
endothelial growth factor
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primer (5) from TaqMan MicroRNA Assays (Applied Biosystems,
Foster City, CA, USA). Real-time polymerase-chain-reaction (PCR)
ampliﬁcationwas performed by Bio-Rad iCycler, version 4.006 (Bio-
Rad Laboratories, Wilmington, North Carolina, USA) using TaqMan
2 Universal PCR Master Mix (No AmpErase UNG) and TaqMan
Assay (20) from TaqMan MicroRNA Assays (Applied Biosystems).
The data were analyzed by iCycler iQ Optical System Software,
version 3.0a (Bio-Rad Laboratories). The relative level of mature
hsa-miR-520h (miR-520h) in HUVECs was calculated against U6
RNA (internal control) using the 2eDDCt method. The PCRs were run
along with the no-template and RT-minus controls.
2.6. Western blot analysis
Equal amounts of protein samples (20 mg) extracted from the
cells were resolved using 12% sodium dodecyl sulfateepoly-
acrylamide gel electrophoresis under a reducing condition, and
subsequently transferred onto a nitrocellulose membrane. After
blotting, themembranewasprobedwithprimaryantibodies against
anti-ephrin receptor (Eph) B2, anti-EphB4 (R&D Systems, MIT,
Boston, USA), and actin (Sigma), and followed by an incubationwith
a secondary antibody. The membrane was then washed and visu-
alized by ECL detection system (Bio-Rad Laboratories). Actin
expression was used as protein loading control. Densitometry
quantiﬁcation was performed in ImageJ software (http://rsb.onfo.
nih.gov). At least three independent experiments were carried out
to study the protein expression.
2.7. In vitro proliferation assay
HUVECs (4  104 cells/well) with or without transfection of Pre-
miR-520h or AS-miR-520h oligonucleotide were seeded onto 96-
well gelatin-coated plates at a density of 1  104 cells/well. The
cells were allowed to grow for 48 h in M199 with 10% HI-FBS at
37C. The metabolic activity was analyzed after the addition of
20 mL of 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium
Bromide (MTT) for 4 h. The formation of a purple formazan solution
was measured at 540 nm and 690 nm.
2.8. In vitro tube-formation assay
HUVECs (2  104 cells/well) with or without transfection of Pre-
miR-520h or AS-miR-520h oligonucleotide were plated onto a 96-
well plate coated with growth-factor-reduced Matrigel (BD Bio-
sciences, Billerica, MA, USA), and incubated at 37C for 8 h. The
tubes that formed in each well were captured using a stereomi-
croscope (Olympus SZX16) with an attached digital camera
(Olympus DP71). The branch points of the tubes that formed in
each well were counted, and the averaged numbers of the branch
points were calculated. Three independent experiments were
performed, and each experiment was run in triplicates.
2.9. In vivo zebra-ﬁsh angiogenesis assay
2.9.1. Maintenance of zebra ﬁsh and collection of embryos
Wild-type zebra ﬁsh were obtained from a local supplier, and
were maintained and bred as described in our previous publication
[16]. The zebra ﬁsh were maintained on a 14 h:10 h light/dark cycle
at 28C, and were fed twice daily with tropical ﬁsh food. Embryos
were generated by natural pair-wise mating when the ﬁsh were
mature (6 months old or above). To prepare for mating, the
breeding tank was submerged into the ﬁsh tank just before
switching on the light in the morning. After 2 h, the embryos were
harvested and transferred to Petri dishes containing fresh water. Allthe animal experiments were approved by the animal ethics
committee of the Hong Kong Baptist University. The procedures
were reported according to the Animal Research: Reporting In Vivo
Experiments guidelines. All procedures performed were meant to
minimize the number of use and suffering of the animals.
2.9.2. Microinjection
Fertilized one- to four-cell-stage zebra-ﬁsh embryos were
injected with 1 pL of 10mM miRNA inhibitor or miRNA precursor
(Ambion). Pre-miR miRNA Precursor Negative Control #1 (Pre-NC;
Ambion) and Anti-miR miRNA Inhibitor Negative Control #1 (Anti-
NC; Ambion) were used as negative controls in this experiment.
The injected embryos were incubated in embryo water (0.2 g/L of
Instant Ocean salt in distilled water) with 0.003% 1-phenyl-2-
thiourea at 28.5C. At least 30 embryos were analyzed in each
experimental condition.
2.9.3. Endogenous alkaline-phosphatase-based vascular staining
After 3 days of incubation (3 days postfertilization), the embryos
were euthanized, andalkaline-phosphatase activitywasassayedafter
overnight ﬁxation at 4C in 4% paraformaldehyde. The endogenous
melanin in theﬁsh-embryopigment cellswas removed by incubating
in 1% KOH and 3% H2O2 for 20 min, followed by 0.1% phosphate-
buffered saline in Tween 20 (PBST) rinsing. Then, ﬁsh embryos were
treated with precooled acetone for 30 min at20C and rinsed with
PBST. For staining, the embryos were equilibrated with NTMT buffer
(100mMTriswithpH9.7, 50mMMgCl2,100mMNaCl, and0.1%Tween
20) at room temperature, and subsequently stained with nitroblue
tetrazolium/5-bromo-4-chloro-3-indolyl-phosphate (AMRESCO, So-
lon, OH, USA) at room temperature in the dark. Finally, the ﬁsh em-
bryos were ﬁxed again in 4% paraformaldehyde followed by PBST
rinsing. The subintestinal-vessel (SIV) basket of the stained zebra ﬁsh
was examined under the stereomicroscope (Olympus SZX16)with an
attached digital camera (Olympus DP71) (Olympus America, Inc.).
Areas of the SIVs were quantiﬁed by the ImageJ software.
2.10. 30-UTR luciferase-reporter assay
Luciferase-reporter vectors containing 30-UTR of EphB2 and
EphB4 were purchased from SwitchGear Genomics, Menlo Park, CA,
J Ginseng Res 2016;40:151e159154USA. To conﬁrm the putative binding site, the seed regions of miR-
520h on EphB2 and EphB4 30-UTR were converted to consecutive
cytosine using QuikChange Lightning Multi Site-Directed Mutagen-
esis Kit (Agilent Technologies). Mutation was conﬁrmed by DNA
sequencing. COS-7 was cultured in Dulbecco’s modiﬁed Eagle’s me-
diumwith 10% fetal bovine serum. Cells seeded onto a 96-well plate
(3  104 cells/well) were cotransfected with the reporter vector
(50 ng) and miRNA synthetic oligonucleotides (50nM) by Lipofect-
amine 2000. After 24 h of transfection, the cell lysate was harvested,
and luciferase activity was detected using Luciferase Assay System
(Promega, Madison, WI, USA) with a microplate luminometer
(Inﬁnite F200; Tecan, Männedorf, Switzerland). The luminescence
reading was normalized by protein content in each well.
2.11. Statistical analysis
Data were presented as mean  standard deviation (SD) unless
otherwise speciﬁed. Statistical comparisons between two groupsFig. 2. The mature hsa-miR-520h (miR-520h) targets on ephrin receptor (Eph) B2 and Eph
520h is partially complementary to the RNA sequence within the EphB2 and EphB4 30-UTR
(MUT) EphB2 and EphB4 messenger RNA 30-UTR was cotransfected with miR-520h precur
deviation. Asterisks denote a signiﬁcant difference compared with the values for the precowere carried out by the Student t test or one-way analysis of vari-
ance (SigmaPlot version 12.5). The statistical signiﬁcance was set as
p < 0.05.
3. Results
3.1. The miRNA-expression proﬁling of Rg3-treated VEGF-induced
HUVECs
As shown in Table 1, among the screened 553 human miRNAs,
nine miRNAs were found to differentially express in VEGF-induced
HUVECs after Rg3 treatment. Among them, both miR-520h and
miR-487b increased more than 10-fold, while four other miRNAs
including miR-219, miR-342, miR-524*, and miR-197, were up-
regulated from 2.36 to 6.89 folds. Besides, three miRNAs, including
miR-23a,miR-489, andmiR-377,were differentially down-regulated
in the range of 3.81e34.94 folds. The microarray data have been
deposited in the Gene Expression Omnibus public database withB4 30-UTR. (A) The computational target prediction of TargetScan suggested that miR-
. (B) Luciferase-reporter plasmid bearing wild-type (WT) or mutated (MUT) mutated
sor or inhibitor (50nM) for 24 h in COS-7. Values are presented as means  standard
ntrol. ***p < 0.001.
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info/linking.html).
3.2. Bioinformatics prediction of potential gene targets of miR-520h
Among the nine miRNA candidates, miR-520h showed the
highest up-regulated level and consistency; it was selected as the
investigation target in this study. Using an online database for
miRNA target prediction (release 6.2: June 2012; http://www.
targetscan.org/), miR-520h is found to be partially complemen-
tary to the RNA sequence extending from nucleotide 990 to 1012
within EphB2 30-UTR, and the sequence extending from nucleotide
85 to 105 within EphB4 30-UTR (Fig. 2A). While ephrin is closely
related to cell migration and angiogenesis, we believed that EphB2
and EphB4 might be the target of miR-520h in Rg3-induced anti-
angiogenesis. To further conﬁrm the interaction of miR-520h on
EphB2 and EphB4 30-UTR, luciferase-reporter vectors containing
the full length of EphB2 or EphB4 messenger RNA (mRNA) 30-UTR
were cotransfected with miRNA precursor mimics (Pre-miR-520h)
or antisense miR-520h (AS-miR-520h) into COS-7. From Fig. 2B,
overexpression of miR-520h could signiﬁcantly inhibit EphB2 and
EphB4 30-UTR luciferase activities for about 60%, while the trans-
fection of miR-520h inhibitor showed no signiﬁcant effects. Mu-
tation of the putative seed region of EphB2 mRNA 30-UTR could
completely abolish the inhibition by overexpression of miR-520h.
However, similar mutation on EphB4 mRNA 30-UTR could only
partially reduce the inhibition by miR-520h, which indicated that
there may be another unidentiﬁed binding site on the 30-UTR.
Otherwise, miR-520h may target on regulator upstream of EphB4,
thus providing an indirect effect.
3.3. Validation of miR-520h expression and potential gene targets
To conﬁrm the overexpression of miR-520h in Rg3-treated
endothelial cells, real-time PCR was performed. Using U6 as inter-
nal control, the ratio of miR-520h to U6 RNA in the control cells was
arbitrarily set at 1. The results showed that the relative expression
of miR-520h was found to increase by 2.98-fold in HUVECs upon
the Rg3 treatment (Fig. 3), which is concomitant to our microarray-Fig. 3. 20(R)-ginsenoside-Rg3 (Rg3) increases the mature hsa-miR-520h (miR-520h)
expression in vascular-endothelial-growth-factor (VEGF)-induced human-umbilical-
vein endothelial cells. The expression level of miR-520h in VEGF-induced human-
umbilical-vein endothelial cells upon Rg3 treatment was measured using quantitative
real-time polymerase chain reaction. The cells were cultured in M199 medium sup-
plemented with 10% heat-inactivated fetal bovine serum and 25 ng/mL VEGF, with or
without Rg3 for 24 h. The relative expression of miR-520h was calculated against U6
RNA with the 2eDDCt method. All polymerase chain reactions were run in triplicates in
at least three independent experiments. Values are presented as means  standard
deviation. The asterisk denotes a signiﬁcant difference compared with the values for
the corresponding control. *p < 0.05.proﬁling data. Besides, the expression levels of EphB2 and EphB4,
which are the potential targets of miR-520h, were measured by
Western blotting analysis. As shown in Fig. 4, the expression level of
EphB2 was almost completely suppressed, while B4 was decreased
by 2.3-fold in Rg3-treated HUVECs.
3.4. Functional roles of miR-520h in angiogenesis
In order to demonstrate the roles of miR-520h in Rg3-induced
angiosuppression, expression levels of target proteins EphB2 and
EphB4, tube formation and proliferation ability of HUVECs, and SIV
formation of zebra-ﬁsh embryos were measured after the intro-
duction of Pre-miR-520h or AS-miR-520h transfection or microin-
jection. As shown in Fig. 5A, when HUVECs were transfected with
Pre-miR-520h, the level of miR-520h was greatly increased, as
measured by quantitative real-time PCR (qRT-PCR) analysis. The
Western blotting analysis indicated that the expression of the
target protein EphB2 was reduced in about 20%, while EphB4 was
totally diminishedwhen comparedwith the control group (Fig. 5B).
Moreover, the functional role of miR-520h was clearly demon-
strated in various bioassays. In Fig. 5C and 5D, overexpression of
miR-520h was found to signiﬁcantly suppress HUVEC proliferation
and tubulogenesis in about 18% and 35%, respectively. Finally, the
in vivo angiogenesis model was employed, and precursor mimics of
miR-520h were injected into the zebra-ﬁsh embryos. Data showed
that the neovessel formation in the SIV basket was signiﬁcantly
suppressed in the presence of miR-520h when compared with the
precontrol group (Fig. 5E). These results suggested that miR-520h
might be important in angiogenesis through modulating EphB2
and EphB4. Conversely, experiments were repeated by transfecting
an antagomiR antisense (AS-miR-520h) to mature miR-520h. With
reference to the internal U6 RNA expression, transfection of AS-Fig. 4. 20(R)-ginsenoside-Rg3 (Rg3) suppresses ephrin receptor (Eph) B2 and EphB4
expression in vascular-endothelial-growth-factor (VEGF)-induced human-umbilical-
vein endothelial cells. Total protein was harvested from treatment (VEGF þ Rg3) and
control (VEGF) group cells. Then, the expression levels of EphB2 and EphB4 were
analyzed by Western blotting with indicated antibodies (upper panel). The relative
expressions of EphB2 and EphB4 were normalized and quantiﬁed against actin (lower
panel). Values are presented as means  standard deviation of three independent
experiments. Asterisks denote a signiﬁcant difference compared with the values for
the corresponding control. **p < 0.01; ***p < 0.001.
Fig. 5. Elevated level of the mature hsa-miR-520h (miR-520h) diminishes ephrin receptor (Eph) B2 and EphB4 expression, human-umbilical-vein-endothelial-cell (HUVEC) pro-
liferation and tubulogenesis, and zebra-ﬁsh subintestinal-vessel (SIV) formation. (A) Transfection of Pre-miR-520h oligonucleotide (20nM) for 24 h signiﬁcantly elevated the miR-
520h level in HUVECs. The miR-520h level was quantitated by quantitative real-time polymerase chain reaction. Three independent experiments were performed, and each
experiment was in three replicates. (B) Increased level of miR-520h suppressed EphB2 and EphB4 expressions in HUVECs. Total protein was harvested from Pre-miR-520h or
precontrol transfected HUVECs, and EphB2 and EphB4 expression levels were measured by Western blotting (upper panel), and quantiﬁed with actin normalization (lower panel).
(C) and (D) Transfection of Pre-miR-520h oligonucleotide suppressed HUVEC proliferation and tubulogenesis. Upon transfection, HUVECs were cultured for 48 h, and growth
inhibition was determined by 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay. Tubulogenesis was measured by counting the number of branch points
formed by HUVECs on the Matrigel. Three independent experiments were performed, and each experiment was in four replicates. (E) Microinjection of Pre-miR-520h into zebra-
ﬁsh embryo greatly inhibited the SIV basket formation. Photomicrographs depict SIV formation in 3 days postfertilization ﬁsh embryo in deﬁned condition. The area of the SIV
basket was measured by ImageJ software. Values are presented as means  standard deviation. Asterisks denote a signiﬁcant difference compared with the values for the cor-
responding control. *p < 0.05, **p < 0.01, ***p < 0.001.
J Ginseng Res 2016;40:151e159156miR-520h signiﬁcantly reduced the endogenous miR-520h level in
HUVECs when compared with the AS-control group (Fig. 6A).
Subsequently, as we expected, the EphB2 and EphB4 expression
levels should be affected to a certain extent. However, it was found
that the EphB2 and EphB4 expression levels in HUVECs were not
much increased upon AS-miR-520h transfection (Fig. 6B). Similar
results were observed in both in vitro and in vivo angiogenic assays,
inwhich there were no measurable changes in HUVEC proliferation
and tube formation (Fig. 6C and 6D), as well as in the zebra-ﬁsh SIV
formation assay (Fig. 6E). To show the inhibitory effect of Rg3 on
angiogenesis, which is indeed mediated through the induction of
miR-520h, HUVECs were ﬁrst transfected with AS-control or AS-
miR-520h, and then VEGF and Rg3 were added to the cells. The
inhibitory effects of Rg3 on HUVEC proliferation (Fig. 7A) and
tubulogenesis (Fig. 7B) were both abolished by the transfection of
AS-miR-520h, which indicated that the increase of expression of
miR-520h is essential to its angiosuppressive effects.
4. Discussion
The anti-angiogenic strategy of cancer therapy has been pro-
posed for more than 40 years, and the ﬁrst anti-angiogenic drug,
Avastin (bevacizumab), was approved by the US Food and DrugAdministration in 2004 for cancer treatment [17]. As predicted, the
focus has been directed toward discovering more novel anti-
angiogenic agents, such as TNP-470 and thalidomide. As
ginsenoside-Rg3 has been packaged as “Shenyi jiaonang” in
mainland China and used for cancer treatment, its pharmacological
mechanisms are still unclear. In this study, we tried to investigate
how Rg3 could inhibit angiogenesis through modulating the
miRNA expression. Data showed that Rg3 could modulate a series
of miRNA expressions in the VEGF-induced HUVECs, whereas miR-
520h was selected from the microarray-based screening for a
detailed study, as it is the most differentially expressed with a
higher degree of consistency.
In fact, there is not much research about miR-520h in the
literature; until recent years, the anticancer activity of miR-520h
was proposed. It has been suggested as a speciﬁc marker for a
better classiﬁcation of oral squamous cell carcinoma, and differ-
entiation of pathologic pregnancies [18,19]. Moreover, Su et al [20]
have provided clinical data about the signiﬁcance of miR-520h in
lung-cancer patients. They demonstrated the possible link between
resveratrol-mediated miR-520h expression and lung-cancer
migration and invasion abilities. They also showed that miR-520h
was critical for adenoviral oncogene-mediated antimetastatic
lung-colony formation in an experimental metastasis and lung-
Fig. 6. Reduced level of the mature hsa-miR-520h (miR-520h) exhibits no effects on ephrin receptor (Eph) B2 and EphB4 expression, human-umbilical-vein-endothelial-cell
(HUVEC) proliferation and tubulogenesis, and zebra-ﬁsh subintestinal-vessel (SIV) formation. (A) Transfection of AS-miR-520h oligonucleotide (20nM) for 24 h effectively
reduced the miR-520h level in HUVECs. The miR-520h level was quantitated by quantitative real-time polymerase chain reaction. Three independent experiments were performed,
and each experiment was in three replicates. (B) Decreased level of miR-520h exhibits no signiﬁcant effect on EphB2 and EphB4 expressions in HUVECs. Total protein was harvested
from AS-miR-520h or AS-control transfected HUVECs, and EphB2 and EphB4 expression levels were measured by Western blotting (upper panel), and quantiﬁed with actin
normalization (lower panel). (C) and (D) Transfection of AS-miR-520h oligonucleotide exerts no effect on HUVEC proliferation and tubulogenesis. After transfection, HUVECs were
cultured for 48 h, and growth inhibition was determined by 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay. Tubulogenesis was measured by counting
the number of branch points formed by HUVECs on the Matrigel. Three independent experiments were performed, and each experiment was in four replicates. (E) Microinjection of
AS-miR-520h into zebra-ﬁsh embryo has no effect on the SIV basket formation. Photomicrographs depict SIV formation in 3 days postfertilization ﬁsh embryo in deﬁned condition.
The area of the SIV basket was measured by ImageJ software. Values are presented as means  standard deviation. Asterisks denote a signiﬁcant difference compared with the
values for the corresponding control. *p < 0.05, **p < 0.01, ***p < 0.001.
M.-H. Keung et al / Rg3 mediated angiosuppression 157colonization model [20,21]. Wang et al [22] also demonstrated that
miR-520h could act as a potent suppressor of pancreatic cancer cell
(PANC-1) migration and invasion via the down-regulation of
breast-cancer-resistance-protein (ABCG2) expression. Obviously,
miR-520h is most likely to mediate cell motility; therefore, we
believed that Rg3-induced miR-520h would also play a critical role
in modulating endothelial-cell motility and resulted in angiosup-
pression. According to the computational-prediction analysis,
among the target proteins of miR-520h, EphB2 and EphB4 were the
most relevant candidates. Indeed, our data showed that Rg3-
induced overexpression of miR-520h resulted in the reduction of
EphB2 and EphB4 proteins. Actually, the Eph family is the largest
receptor-tyrosine-kinase family; the activation of Eph receptor by
their membrane-anchored ligands (ephrins) (Epheephrin interac-
tion) mediates the critical steps of angiogenesis and vascular-
network formation, including endothelial cell-to-endothelial/
surrounding-mesenchymal-cell interactions, cell adhesion to
extracellular matrix, and cell migration [23e25]. Moreover, it has
been shown that ephrin-B ligand and Eph-B receptor induced
angiogenic sprouting by stimulating reverse and forward
signaling [26]. Besides, as the downstream signaling of EphB4 in-
cludes the key pathway of angiogenesis, such as phosphatidylino-
sitol-3-kinase/Akt/endothelial nitric oxide synthase/protein kinaseG/mitogen-activated-protein-kinase cascade, and matrix metallo
proteinase-2 and -9 production [27], it implicated that suppres-
sion of Ephs could signiﬁcantly interrupt a lot of cellular activities,
including cell proliferation and migration. Indeed, this inhibitory
pathwaywould be one of the angiosuppressive mechanisms of Rg3.
However, a recent ﬁnding proposed that Eph/ephrin signaling
mechanism might also correlate with VEGF-induced angiogenesis
and VEGFR function in developmental and tumor angiogenesis
[28,29]. As suggested by Sawamiphak et al [30], the Eph/ephrin
signaling at the tip-cell ﬁlopodia could regulate the proper
spatial activation of VEGFR-2 endocytosis, and signaling to direct
the ﬁlopodial extension. Subsequently, it could control the
vascular morphogenesis and sprouting angiogenesis [30].
Meanwhile, the internalization of VEGFR-2 and -3 was found to
depend on Eph/ephrin signaling [31,32], whereas we have also
found that Rg3 could suppress VEGFR-2 production in HUVECs
(data not shown). This implicated that the Rg3-induced down-
regulation of EphB2 and EphB4 in endothelial cells (receptor-
expressing cells) might suppress the reverse-signaling pathway
of the adjacent ephrin-ligand-expressing cells (including tumor
and endothelial cells), and resulted in the inhibition of VEGFR-2
expression and subsequent VEGF signaling that lead to
angiosuppression.
Fig. 7. Decreased level of the mature hsa-miR-520h (miR-520h) abolishes the angio-
suppressive effects of 20(R)-ginsenoside-Rg3 (Rg3) on human-umbilical-vein endo-
thelial cells (HUVECs). HUVECs were transfected with AS-control or AS-miR-520h
oligonucleotide (20nM) for 24 h, followed by treatment with vascular endothelial
growth factor (VEGF) alone or VEGF þ Rg3. (A) After Rg3 treatment, HUVECs were
cultured for 48 h, and cell proliferation was determined by 3-(4,5-Dimethylthiazol-2-
yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay. (B) Tubulogenesis was measured by
counting the number of branch points formed by HUVECs on the Matrigel. Three in-
dependent experiments were performed, and each experiment was in four replicates.
Values are presented as means  standard deviation. Asterisk denotes a signiﬁcant
difference compared with the values for the corresponding control. **p < 0.01,
***p < 0.001.
J Ginseng Res 2016;40:151e159158In recent years, the therapeutic potential and pharmacological
mechanisms of natural phytochemicals have been of great interest.
Ginsenoside is one of the pharmacological active compounds that
have been studied in detail for their diverse effects [33e36].
5. Conclusion
In this study, we demonstrated that Rg3-induced angiosup-
pression could be mediated by miR-520h, whereas miR-520h is
proposed to negatively regulate angiogenesis through suppressing
EphB2 and EphB4 expressions, as shown in the inhibition of pro-
liferation and tubulogenesis of HUVECs, and the SIV formation of
zebra ﬁsh. These ﬁndings further supplement the lack of informa-
tion on the angiosuppressive mechanism of Rg3. Furthermore, the
regulations of Eph/ephrin molecules and miRNAs have been re-
ported as molecular targets for therapeutic approaches; this im-
plicates a great potential for developing Rg3 as a potent
angiosuppressive agent.Conﬂict of interest statement
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